Biocon Limited is India's premier biopharma enterprise focused on innovation to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe.
Overview:
Established in 1978 by Ms Kiran Mazumdar-Shaw, Biocon is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases to provide access to affordable treatment to patients across the global.
Biocon's key innovations include world's first Pichia based recombinant human Insulin, INSUGEN®, insulin analogue Glargine, BASALOG® and India's first indigenously produced monoclonal antibody BioMAb-EGFR® , for head & neck cancer. INSUPen® is a next generation affordable insulin delivery device introduced in India.
With a risk balanced business model comprising small molecules, novel molecules, biosimilars, branded formulations and research services, Biocon has evolved into an emerging global enterprise serving its partners and customers in over 70 countries
Shared 22 hours ago
242 views
Shared 3 days ago
1.4K views
Shared 4 months ago
56 views
Shared 7 months ago
685 views
Shared 10 months ago
553 views
Shared 1 year ago
942 views
Shared 1 year ago
84 views
Shared 1 year ago
761 views
Shared 1 year ago
83 views
Shared 1 year ago
4.9K views
Shared 1 year ago
618 views
Shared 1 year ago
1.2K views
Shared 2 years ago
1.5K views
Shared 2 years ago
1.8K views
Shared 2 years ago
1K views
Shared 2 years ago
661 views
Kiran Mazumdar - Shaw,Executive Chairperson, Biocon & Biocon Biologics speaking on Q4 & FY23 Results
Shared 3 years ago
700 views
Shared 3 years ago
246 views
Shared 3 years ago
897 views
Shared 3 years ago
345 views
Shared 3 years ago
958 views
Shared 3 years ago
5.5K views
Shared 3 years ago
7.2K views
Shared 3 years ago
297 views
Shared 3 years ago
1.5K views
Shared 4 years ago
2.3K views
Shared 4 years ago
590 views
Shared 4 years ago
359 views
Shared 4 years ago
1K views
Shared 4 years ago
90 views
Shared 4 years ago
113 views